Nurix Therapeutics Inc. (NRIX): Price and Financial Metrics
NRIX Price/Volume Stats
| Current price | $13.59 | 52-week high | $18.12 |
| Prev. close | $14.44 | 52-week low | $4.22 |
| Day low | $12.95 | Volume | 1,017,278 |
| Day high | $14.84 | Avg. volume | 952,106 |
| 50-day MA | $13.08 | Dividend yield | N/A |
| 200-day MA | $9.34 | Market Cap | 667.96M |
NRIX Stock Price Chart Interactive Chart >
Nurix Therapeutics Inc. (NRIX) Company Bio
Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Latest NRIX News From Around the Web
Below are the latest news stories about NURIX THERAPEUTICS INC that investors may wish to consider to help them evaluate NRIX as an investment opportunity.
CFO Houte Van Sells 10,906 Shares of Nurix Therapeutics IncOn December 19, 2023, Houte Van, the CFO of Nurix Therapeutics Inc (NASDAQ:NRIX), executed a sale of 10,906 shares in the company, according to a recent SEC Filing. |
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Price Is Right But Growth Is Lacking After Shares Rocket 44%Those holding Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares would be relieved that the share price has rebounded 44... |
Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of DirectorsFORT WASHINGTON, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE: TOL) (TollBrothers.com), the nation’s leading builder of luxury homes, today announced that Judith A. Reinsdorf and Katherine M. Sandstrom have joined the Company’s Board of Directors. In addition, Carl B. Marbach, age 82, has informed the Company that he will not stand for re-election and will step down from the Board at its next annual meeting of stockholders in March 2024. Ms. Reinsdorf, age 59, most recently s |
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual MeetingPositive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL) Rapid durable complete responses in a heavily pretreated relapsed/refractory patient population support continued development of NX-2127 in non-Hodgkin lymphoma (NHL) Nurix will webcast a Key Opinion Leader (KOL) event at 8:30 p.m. PT today to review data presented at the ASH meeting from its BTK degrader portfolio SAN FRANCISCO, Dec. 11, 2023 (GLOBE N |
Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual MeetingSAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it will host a live webcast to review clinical data from the Phase 1 clinical trials of its Bruton’s tyrosine kinase (BTK) degrader programs, NX-5945 and NX-2127, which are being evaluated in patients with relapsed or refracto |
NRIX Price Returns
| 1-mo | 2.33% |
| 3-mo | 66.54% |
| 6-mo | 184.31% |
| 1-year | 25.02% |
| 3-year | -54.04% |
| 5-year | N/A |
| YTD | 31.69% |
| 2023 | -6.01% |
| 2022 | -62.07% |
| 2021 | -11.95% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...